Olga V. Demler, PhD
Assistant Professor of Medicine, Harvard Medical School
Associate Biostatistician, Brigham and Women’s Hospital
odemler@bwh.harvard.edu
Dr. Demler is a biostatistician who oversees the design and statistical analysis of a number of metabolomic studies and interventional clinical trials. Dr. Demler received her Ph.D. degree from Boston University where she worked with Drs D’Agostino and Pencina on the statistical assessment of risk prediction models. She continues this work at the Division, and developed a goodness fit tests in survival setting and for reclassification-calibration statistic with Drs Cook and Paynter. Her methodological research interests include development of rigorous analytic workflows for analyzing metabolomics data and Electronic Medical Records. Dr. Demler’s clinical research interests include cardiovascular disease prevention, lipids, biomarker research, and women’s health. Dr. Demler provides statistical leadership in the analysis of randomized clinical trials and observational studies including Framingham Heart Study, Women’s Health Study, JUPITER trial, the VITaminD and OmegA-3 TriaL (VITAL). Dr. Demler was awarded a five-year career development award (K01) from the National Heart, Lung, and Blood Institute to investigate coronary heart disease risk and metabolic profiles of individuals with discordant lipids. Dr. Demler is also leading a project funded by the American Heart Association on building a flexible predictive network using large-scale database of Electronic Medical Records from several major Boston-area hospitals.
MS: Stanford University
MA: University of California at Santa Barbara
PhD: Boston University
Full Listing of Publications
- Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial November 3, 2024CONCLUSIONS: Each of insulin, C-peptide, IRS, and HbA1c were associated with incident T2D with the strongest association noted for HbA1c. While HbA1c was significantly associated with CVD risk, a novel IRS appears to be associated with CHD risk. Neither vitamin D nor n-3 FA modified the associations between these biomarkers and cardiometabolic outcomes.Frank Qian
- One-Year Effects of High-Intensity Statin on Bioactive Lipids: Findings From the JUPITER Trial June 6, 2024CONCLUSIONS: Statin allocation was significantly associated with upregulation of BALs with anti-inflammatory, antiplatelet aggregation and antioxidant properties and downregulation of BALs with proinflammatory and proplatelet aggregation activity, supporting the pleiotropic effects of statins beyond low-density lipoprotein cholesterol reduction.Rosangela Akemi Hoshi
- Mediterranean Diet Adherence and Risk of All-Cause Mortality in Women May 31, 2024CONCLUSIONS AND RELEVANCE: In this cohort study, higher adherence to the Mediterranean diet was associated with 23% lower risk of all-cause mortality. This inverse association was partially explained by multiple cardiometabolic factors.Shafqat Ahmad
- Defining a Minimal Benchmark for Cardiovascular Risk Prediction Calculators in New England Electronic Health Record-Derived Cohort May 30, 2024No abstractAniket N Zinzuwadia
- Plasma Biomarker Profiles for Premature and Nonpremature Coronary Heart Disease in Women March 12, 2024CONCLUSIONS: In women, a profile of 12 biomarkers was selectively associated with premature CHD, driven by lipoprotein(a) and insulin-resistant atherogenic dyslipoproteinemia. This has implications for the development of biomarker panels to screen for premature CHD.Sagar B Dugani